DETAILED WORK ON HOW TO PRODUCE TOILET SOAPFull description
Epichlorohydrin is a valuable fine chemical, mainly dedicated to the manufacturing of epoxy resins. Currently, several routes are available for the production of this chemical with the predominant ...
theory of productionFull description
Production of Butyl Rubber
production function
The Production of SpaceFull description
design project for production of acetaldehyde
design project for production of acetaldehydeDescripción completa
economics
production of phenol from benzeneFull description
Fruit ProductionFull description
Production of Acetone
music production
Production of Insulin.Descripción completa
article
Production of
1
PRODUCTION OF A FFO RDA DAB BLE CHEM O THERA PY M . Sja Sja msul Arif A rif in Pr es esid id ent Direc Dire ctor of PT. Kimia Fa r ma. Tb Tb k
2
AG EN DA … . 1. 2. 3. 4.
G LO BA L CA CAN N CE CER R M A RKE KET T IN DO N ESIA N PHA HAR RM A M A RKE KET T KF EFFO RT SUMMARY
G LO BA L CA CAN N CE CER R … … .. M a rket Size: Size: 6 5 b illion USD USD G row th Ra te: 2 3 % Third biggest therapy class O ut of 8 2 b lockb lockbuuster d rug rug s 7 a re a ntica tica ncer* *MabThera, Glivec, Eloxatin, Gemzar, Casodex, Taxotere & Zometa 3
Business Source:
Wire – , 2008 – IMS Health
CAN CA N CE CER R IN INCIDE CIDEN N CE G LO BA LLY … . 4
18,30% 17,90% 14,60% 12,20% 11,50%
5,50%
5,20%
3,60%
3,40%
2,30%
2,20%
1,80%
1,60%
TO P 5 CA CAN N CE CER RS G LO BA BALLLY BY BY G EN DE DER R … .. TOP 5 IN FEMALES
36.70%
Breast
Large Bowel
17.30%
Melanoma of Skin TOP 5 IN MALES
18.50%
Large Bowel
14.10%
Lung Melanoma of Skin Non Hodgkins Lymphoma
5
12.90% 4.90%
8.90%
Lung
29.20%
Prostate
11.40%
Non Hodgkins Lymphoma
0.10%
UN IQ UE THE HER RA PHY BEHA HAV V IO UR … … ..
Note : 50% of growth is driven by New Drugs 6
7
INDO IN DO N ESIAN PHA HAR RM A M A RKE KET T….
8
9
MARKET ANALYSIS ( Cancer Product ) … 10
Value Val ue : IDR Billions
RA N K
CO M PA N Y
2008
G %
2007
G %
2006
1
LC
144
(7 .7 )
156
2 1 .4
156
2
MNC
78
3 5 .2
58
3 1 .9
44
3
MNC
43
5 .9
40
5 2 .9
27
4
LC
28
36 3 6 .8
20
3 2 .7
15
5
LC
27
4 .2
26
1 1 .2
23
6
MNC
25
(7 .9 )
28
1 0 .9
25
Bas ased ed on IT ITMA Data MAT Dec 20 0 8
KF a s a sta te O w n Com Compp a ny … 11
¨
W e have ha ve b usines inesss f rom ro m d ow n strea tre a m to up strea tre a m : ¤
W e a lso lso ha ha ve ma ma ny ra ng e of p rod ucts & to ser ser ve ma ny customers ( p riva te sector & g overnm ove rnment ent sector sector )
KF EF EFFO RT … . 12
q
q
q
KF will develop strategic products for Cancer & HIV AIDS KF w w ill coop coop era tion with w ith na na tional Insura nce & Ca ncer Hospital KF w ill ha ha ve a colla b ora tion w ith ith:: q
q q
Domestic Partner : BATAN Foreign Pa rtn rtner er : Na p rod & 3 M
In f utu ture re KF w ill b uild a Pla nt f or d evelop in ingg Ca Canncer & HI HIV V p rod ucts (a lrea d y f in inis ishhed )
13
Pr eve evenntio tionn Ca Ca ncer Ther eraa p eu eutic ticss 1. 2. 3. 4.
Ea r ly Dete Detecction a nd Scre reenin eningg Dia g nos osis is a nd Tr ea tmen tmentt Sup p or ortt a nd Reh ehaa b ilitation Pa lliative Ca re
14
STRA TEG YC PRO PRO DU DUC CT FO R CA N CE CER R
LIS IST T PRO DUCT O N CO LO G Y BY BY KF (N (NA A PRO D) … … .. N o . Pr o d uc uct N am a me
St r e ng ht ht
Pa ck ck si ze
1
N a p r o - Ta x
Pa cl i t a x e l 3 0 mg
6 mg /
ml
v i a l 5 ml
2
Ci st e e n
C i sp l a t i n 1 0 mg
1 mg /
m l
v i a l 1 0 ml
3
Ci st e e n
C i sp l a t i n 5 0 mg
1 mg /
m l
v i a l 5 0 ml
4
A l lt r e x
M e t ho t r e x a t e 5 0 mg
2 5 mg / ml
v i a l 2 ml
5
A l lt r e x
M e t ho t r e x a t e 2 .5 mg
t a b l e t 2 .5 mg
1 0 0 ta b
6
N a p r o ci l
5 - Fl uo ur o ur a ci l 5 0 0 mg
1 0 0 mg / ml
v i a l 1 0 mg
7
N a p rod ox
D o x o r ub i ci n 1 0 mg
2 mg /
ml
v i a l 5 ml
8
N a p rod ox
D o x o r ub i ci n 5 0 mg
2 mg /
ml
v i a l 2 5 ml
9
N zy top
Et o p o si d e 1 0 0 mg
2 0 mg /
ml
v i a l 5 ml
10
Xi f e n
Ta mo x i f e n 1 0 mg
1 0 mg /
ca p sul
1 0 x 1 0 ca p
11
Xi f e n
Ta mo x i f e n 2 0 mg
2 0 mg /
ca p sul
1 0 x 1 0 ca p
C y cl o p ho sp ha mi d i e
5 0 0 mg
vi a l
12
15
A ct i ve Pha rm r ma Ing
13
Ta ce e d o
D o ci t a x e l
2 0 mg
vi a l
14 15
Ta ce e d o 4 -E - Ep ee e e d oo-1 0
D o ci t a x e l Ep irir ub ub ic i ci n
8 0 mg 1 0 mg
vi a l vi a l
16
4 -E - Ep ee e e d oo-5 0
Ep irir ub ub ic i ci n
5 0 mg
vi a l
17
A b i ng e m – 2 0 0
G e mci t a b i ne i nj
2 0 0 mg
vi a l
18
A b i ng e m – 1 G r
G e mci t a b i ne i nj
1 .0 0 0 mg
vi a l
16
17
To Produce Affordable Price 18
¨
To make ma ke cop cop y p rod uct ¤
¤
¤
¨ ¨
Cooperation with Naprod (specialist oncology product) 1 8 SKU p rod uct chem chemotera otera py Sa ving ving Cost Cost ( 20 % – 5 0 % EP )
Ea sy to g et a nd a vala va la ila b le in a ll pr ovinc ovinces Q ua lity lity g ua ra nteed
P R I C E 19
C O M P A R A T I V E
Epirubicin 10 mg
4 - Ep eed o - 1 0 Ep i r u b i c i n
N ap r o d Ko m p et i t o r
1 8 5 .0 0 0 2 3 0 .0 0 0
Price Ratio (%) 80 10 0
Epirubicin 50 mg
4 - Ep eed o - 5 0 Ep i ru ru b ic ic in in
N ap r o d Ko m p et et i t or or
9 0 0 .0 0 0 1 . 13 13 0 .0 .0 0 0
80 10 0
Taceed o 2 0 Taxotere Taxotere Brexel rexel
N ap r o d Kompetitor ompetitor A Kompetitor ompetitor B
RAT ATIIO N A L DR DRUG UG US USE E (W HO 2 0 0 1 ) 20
q
Patients receive medicines appropriate to their clinic linicaa l nee needd s
q
Doses that meet their individual requirement.
q
For a n a d eq ua te p eriod of tim ti me
q
The lowest cost to them and their community
21
W HA H A T IS … .B .BIO IO - EQ UIV UIVA A LEN T 22
G EN ERIC DRUG SUBS SUBST TIT ITU UTE REQ UIR IRE EM EN T … 23
Source : FDA Division of Bioequivalence
To Cond Conduuct Sin inee r g y … . 24
¨
¨
¨ ¨
To support & supply government needs for Social Health Insurance To ma ma ke co co -op era tion w ith N a tiona tiona l Hea lth Insurance Co-op era tion w ith Can Ca ncer Hosp Hosp ita l Mutual benefit for government, health insurance corporate, hospitals and public to complete cancer treatments
25
SUM M A RY … .. q
q
KF committed to launch chemotherapy product & af forda ble pric price KF committed to assist government health program
q
Sin inerg erg y p rog ra m w ith g overn overnm met, hea lth insuura nce , hos ins hospp ita ls f or imp implementin lementingg of integ in teg ra ted ca ncer trea tm tmen entt
